Erika D. Penz

Dr. Erika D. Penz

College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5A2, Canada

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in The Lancet Oncology
Verified
Journal Article
Open access
ACAmelia O Clive
Amelia O Clive
HTHazel Taylor
Hazel Taylor
LDLee Dobson
Lee Dobson
PWPaula Wilson
Paula Wilson
EWEmma de Winton
Emma de Winton
NMNick Maskell
Nick Maskell
The use of prophylactic radiotherapy to prevent procedure-tract metastases (PTMs) in malignant pleural mesothelioma remains controversial, and clinical practice varies worldwide. We aimed to compare prophylactic radiotherapy with deferred radiotherapy (given only when a PTM developed) in a suitably powered trial. We did a multicentre, open-label, phase 3, randomised controlled trial in 22 UK hospitals of patients with histocytologically proven mesothelioma who had undergone large-bore pleural interventions in the 35 days prior to recruitment. Eligible patients were randomised (1:1), using a computer-generated sequence, to receive immediate radiotherapy (21 Gy in three fractions within 42 days of the pleural intervention) or deferred radiotherapy (same dose given within 35 days of PTM diagnosis). Randomisation was minimised by histological subtype, surgical versus non-surgical procedure, and pleural procedure (indwelling pleural catheter vs other). The primary outcome was the incidence of PTM within 7 cm of the site of pleural intervention within 12 months from randomisation, assessed in the intention-to-treat population. This trial is registered with ISRCTN, number ISRCTN72767336. Between Dec 23, 2011, and Aug 4, 2014, we randomised 203 patients to receive immediate radiotherapy (n=102) or deferred radiotherapy (n=101). The patients were well matched at baseline. No significant difference was seen in PTM incidence in the immediate and deferred radiotherapy groups (nine [9%] vs 16 [16%]; odds ratio 0·51 [95% CI 0·19-1·32]; p=0·14). The only serious adverse event related to a PTM or radiotherapy was development of a painful PTM within the radiotherapy field that required hospital admission for symptom control in one patient who received immediate radiotherapy. Common adverse events of immediate radiotherapy were skin toxicity (grade 1 in 50 [54%] and grade 2 in four [4%] of 92 patients vs grade 1 in three [60%] and grade 2 in two [40%] of five patients in the deferred radiotherapy group who received radiotherapy for a PTM) and tiredness or lethargy (36 [39%] in the immediate radiotherapy group vs two [40%] in the deferred radiotherapy group) within 3 months of receiving radiotherapy. Routine use of prophylactic radiotherapy in all patients with mesothelioma after large-bore thoracic interventions is not justified. Research for Patient Benefit Programme from the UK National Institute for Health Research.

1 June 2017 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
Erika D. PenzErika D. Penz
Erika D. Penz
KWKristina N Watt
Kristina N Watt
CHChristopher A Hergott
Christopher A Hergott
NRNajib Rahman
Najib Rahman
IPIoannis Psallidas
Ioannis Psallidas
Malignant pleural effusion (MPE) is a sign of advanced cancer and is associated with significant symptom burden and mortality. To date, management has been palliative in nature with a focus on draining the pleural space, with therapies aimed at preventing recurrence or providing intermittent drainage through indwelling catheters. Given that patients with MPEs are heterogeneous with respect to their cancer type and response to systemic therapy, functional status, and pleural milieu, response to MPE therapy is also heterogeneous and difficult to predict. Furthermore, the impact of therapies on important patient outcomes has only recently been evaluated consistently in clinical trials and cohort studies. In this review, we examine patient outcomes that have been studied to date, address the question of which are most important for managing patients, and review the literature related to the expected value for money (cost-effectiveness) of indwelling pleural catheters relative to traditionally recommended approaches.

1 March 2015 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
Erika D. PenzErika D. Penz
Erika D. Penz
JBJ. Boffa
J. Boffa
DRD. J. Roberts
D. J. Roberts
DFD. Fisher
D. Fisher
RCR. Cooper
R. Cooper
MJM. T. James
M. T. James
BACKGROUND: Xpert® MTB/RIF is a commercially available nucleic acid amplification test developed for the diagnosis of pulmonary tuberculosis (PTB). OBJECTIVE: To determine the diagnostic accuracy of Xpert for the detection of extra-pulmonary tuberculosis (EPTB). METHODS: We searched MEDLINE, EMBASE and Global Health databases from January 2010 to 15 August 2014 for studies of diagnostic performance in which Xpert was examined against culture for patients with clinically suspected EPTB. Bivariate random effects models were used to provide pooled estimates of diagnostic accuracy. RESULTS: Thirty-six studies were identified, with a pooled sensitivity and specificity of respectively 77% (95%CI 66–85) and 97% (95%CI 94–98). Substantial variations existed between study estimates of sensitivity (I 2 = 99%) and specificity (I 2 = 96%). Among site-specific estimates for lymph, pleural fluid, cerebrospinal fluid, gastro-intestinal and urinary samples, the pooled sensitivity was lower in pleural fluid (37%, 95%CI 26–50, meta-regression P < 0.001) and higher in lymph node samples (87%, 95%CI 75–95, meta-regression P = 0.03). CONCLUSION: Xpert has high specificity but limited sensitivity for the detection of EPTB. Although positive Xpert test results may be useful in rapidly identifying EPTB cases, negative test results provide less certainty for ruling out disease.

1 October 2014 in Chest
Verified
Journal Article
Closed access
Erika D. PenzErika D. Penz
Erika D. Penz
EMEleanor K. Mishra
Eleanor K. Mishra
HDHelen E. Davies
Helen E. Davies
BMBraden J. Manns
Braden J. Manns
RMRobert F. Miller
Robert F. Miller
NRNajib Rahman
Najib Rahman

16 December 2016 in Respirology
Verified
Journal Article
Open access
PDF file
JOJordan A.P. Olfert
Jordan A.P. Olfert
Erika D. PenzErika D. Penz
Erika D. Penz
BMBraden J. Manns
Braden J. Manns
EMEleanor K. Mishra
Eleanor K. Mishra
HDHelen E. Davies
Helen E. Davies
NRNajib Rahman
Najib Rahman
Background and objective: Malignant pleural effusion is associated with morbidity and mortality. A randomized controlled trial previously compared clinical outcomes and resource use with indwelling pleural catheter (IPC) and talc pleurodesis in this population. Using unpublished quality of life data, we estimate the cost‐effectiveness of IPC compared with talc pleurodesis.Methods: Healthcare utilization and costs were captured during the trial. Utility weights produced by the EuroQol Group five‐dimensional three‐level questionnaire and survival were used to determine quality‐adjusted life‐years (QALYs) gained. The incremental cost‐effectiveness ratio (ICER) was calculated over the 1‐year trial period. Sensitivity analysis used patient survival data and modelled additional nursing time required per week for catheter drainage.Results: Utility scores, cost and QALYs gained did not differ significantly between groups. The ICER for IPC compared with talc was favorable at $US10 870 per QALY gained. IPC was less costly with a probability exceeding 95% of being cost‐effective when survival was <14 weeks, and was more costly when 2‐h nursing time per week was assumed for catheter drainage.Conclusion: IPC is cost‐effective when compared with talc, although substantial uncertainty exists around this estimate. IPC appears most cost‐effective in patients with limited survival. If significant nursing time is required for catheter drainage, IPC becomes less likely to be cost‐effective. Either therapy may be considered as a first‐line option in treating malignant pleural effusion in patients without history of prior pleurodesis, with consideration for patient survival, support and preferences.

1 April 2020 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
CTChristina Thornton
Christina Thornton
WTWillis H. Tsai
Willis H. Tsai
MSMaria J. Santana
Maria J. Santana
Erika D. PenzErika D. Penz
Erika D. Penz
WFW. Ward Flemons
W. Ward Flemons
SPSachin R. Pendharkar
Sachin R. Pendharkar
Sleep-disordered breathing (SDB) comprises several entities, including obstructive sleep apnea (OSA), central sleep apnea, and sleep-related hypoventilation.1 The most common type of SDB is OSA; in adults aged 30 to 70 years, the estimated prevalence of OSA (defined by an apnea-hypopnea index of at least 5 events per hour as measured by polysomnography [PSG]) is 34% in men and 17% in women.2,3 Untreated OSA is associated with increased cardiometabolic risk and excessive sleepiness, leading to poor quality of life, depression, and a higher risk of motor vehicle crashes. Patients with severe OSA (defined as apnea-hypopnea index >30 events per hour) have a 2- to 3-fold increased risk of all-cause mortality compared with the general population.4